Physician profile
Tian Xia
NPI 1023402260
$5,806.00
in general payments reported to CMS, 2019-2025
18 companies · $753 in 2025
The $753 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2021: $293 · 2022: $309 · 2023: $530 · 2024: $3,675 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,326 · Food and Beverage: $1,632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,325.50 |
| Food and Beverage | $1,631.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $3,401.01 | 2021-2024 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $442.74 | 2022-2025 | Syfovre |
| Abbvie INC. | $423.45 | 2023-2025 | Ozurdex |
| Alcon Vision LLC | $351.49 | 2019-2025 | Rocklatan |
| Allergan, INC. | $219.44 | 2019-2021 | |
| New World Medical,INC. | $197.28 | 2023 | |
| Genentech USA, INC. | $170.46 | 2023-2025 | Vabysmo, Lucentis |
| Sight Sciences, INC. | $145.32 | 2021 | |
| Novartis Pharmaceuticals Corporation | $100.03 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $83.51 | 2023-2025 | Eylea Hd, Eylea |
| Astellas Pharma US INC | $74.94 | 2025 | Izervay |
| Biotissue Holdings INC. | $57.78 | 2023 | |
| Coherus Oncology, INC. | $33.95 | 2023 | |
| US Oncology Corporate, INC. | $29.10 | 2025 | |
| Biogen, INC. | $28.17 | 2024 | Byooviz |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $16.51 | 2025 | Iheezo |
| Horizon Therapeutics Plc | $16.18 | 2023 | Tepezza |
| Alimera Sciences, INC. | $14.64 | 2023 | Iluvien |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tian Xia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.